Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2006035051) A BACTERIAL ATP SYNTHASE BINDING DOMAIN
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2006/035051 International Application No.: PCT/EP2005/054893
Publication Date: 06.04.2006 International Filing Date: 28.09.2005
IPC:
C07K 14/35 (2006.01) ,C12N 15/31 (2006.01) ,C12N 15/52 (2006.01) ,G01N 33/50 (2006.01) ,A61K 31/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195
from bacteria
35
from Mycobacteriaceae (F)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
31
Genes encoding microbial proteins, e.g. enterotoxins
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
52
Genes encoding for enzymes or proenzymes
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
Applicants:
ANDRIES, Koenraad, Jozef, Lodewijk, Marcel [BE/BE]; BE (UsOnly)
GÖHLMANN, Hinrich, Wilhelm, Helmut [DE/NL]; BE (UsOnly)
NEEFS, Jean-Marc, Edmond, Fernand, Marie [BE/BE]; BE (UsOnly)
VERHASSELT, Peter, Karel, Maria [BE/BE]; BE (UsOnly)
WINKLER, Johann [AT/BE]; BE (UsOnly)
DE JONGE, Marc, René [NL/NL]; BE (UsOnly)
KOYMANS, Lucien, Maria, Henricus [NL/BE]; BE (UsOnly)
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30 B-2340 Beerse, BE (AllExceptUS)
Inventors:
ANDRIES, Koenraad, Jozef, Lodewijk, Marcel; BE
GÖHLMANN, Hinrich, Wilhelm, Helmut; BE
NEEFS, Jean-Marc, Edmond, Fernand, Marie; BE
VERHASSELT, Peter, Karel, Maria; BE
WINKLER, Johann; BE
DE JONGE, Marc, René; BE
KOYMANS, Lucien, Maria, Henricus; BE
Common
Representative:
JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30 B-2340 Beerse, BE
Priority Data:
04104720.028.09.2004EP
60/620,50020.10.2004US
Title (EN) A BACTERIAL ATP SYNTHASE BINDING DOMAIN
(FR) DOMAINE DE LIAISON D'ATP SYNTASE BACTERIENNE
Abstract:
(EN) This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject.
(FR) L'invention concerne une protéine atpE mutante isolée et l'identification d'un domaine de liaison d'ATPase basé sur ladite protéine mutante. Elle concerne également des acides nucléiques, des vecteurs, des cellules hôtes, des compositions pharmaceutiques et des articles associés. Elle concerne, de plus, des méthodes servant à déterminer si un composé d'essai entre en interaction avec la protéine atpE, à savoir, avec le domaine de fixation d'ATPase, ainsi que des compositions pharmaceutiques contenant ledit composé d'essai, en particulier, sous forme d'agent antimicrobien, plus particulièrement, en tant qu'agent antimycobactérien, et encore plus particulièrement, en tant qu'agent servant à traiter la tuberculose chez un individu.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)